Triple-Drug attack aims to wipe out mantle cell lymphoma

NCT ID NCT03872180

Ongoing Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether combining three drugs—bendamustine, obinutuzumab, and venetoclax—can improve outcomes for people with untreated mantle cell lymphoma. Bendamustine and venetoclax are chemotherapy drugs that kill or stop cancer cells from growing, while obinutuzumab is an immunotherapy that helps the immune system attack the cancer. The study enrolls about 23 participants and measures how many achieve a complete response (no detectable cancer) after initial treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bendamustine, obinutuzumab, and venetoclax
What this could lead to: If successful, this combination could become a more effective first-line treatment for mantle cell lymphoma, potentially leading to deeper remissions and longer disease control.
What could go wrong: This is a small, early-phase trial (23 participants) without a comparison group, so results may not apply broadly. The drug combination can cause significant side effects, including low blood counts and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CCND1 POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CCND1 POSITIVE MANTLE CELL LYMPHOMA T(11;14) POSITIVE

Contacts and locations

Locations

Emory Johns Creek Hospital

Johns Creek, Georgia, 30097, United States
Emory Saint Joseph's Hospital

Atlanta, Georgia, 30342, United States
Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.